Outcomes after Ross procedure in adult patients: A meta-analysis and microsimulation

Serena Sibilio, Alex Koziarz, Emilie P. Belley-Côté, Graham R. McClure, Sarah MacIsaac, Seleman J. Reza, Kevin J. Um, Alexandra Lengyel, Pablo Mendoza, Ali Alsagheir, Hatim Alraddadi, Saurabh Gupta, Adriaan W. Schneider, Parth M. Patel, John Brown, Michael W.A. Chu, Mark D. Peterson, Maral Ouzounian, Domenico Paparella, Ismail El-HamamsyRichard P. Whitlock

Research output: Contribution to journalArticle

Abstract

Objective: We conducted a meta-analysis to estimate the risk of adverse events, life expectancy, and event-free life expectancy after the Ross procedure in adults. Methods: We searched databases for reports evaluating the Ross procedure in patients aged more than or equal to 16 years of age. A microsimulation model was used to evaluate age- and gender-specific life expectancy for patients undergoing the Ross procedure. Results: Data were pooled from 63 articles totaling 19 155 patients from 20 countries. Perioperative mortality was 2.5% (95% confidence interval [CI]: 1.9-3.1; N = 9978). We found a mortality risk of 5.9% (95% CI: 4.8-7.2) at a mean follow-up of 7.2 years (N = 7573). The rate of perioperative clinically significant bleeding was 1.0% (95% CI: 0.1-3.0); re-exploration for bleeding 4.6% (95% CI: 3.1-6.3); postoperative clinically significant bleeding from 30 days until a mean of 7.1 years was 0.5% (95% CI: 0.2-1.0). At a mean of 6.9 years of follow-up, reintervention rate of any operated valve was 7.9% (95% CI: 5.7-10.3). The risk of valve thrombosis was 0.3% (95% CI: 0.2-0.5) at 7.6 years; peripheral embolism 0.3% (95% CI: 0.2-0.4) at 6.4 years; stroke 0.9% (95% CI: 0.7-1.2) at 6.5 years; and endocarditis 2.1% (95% CI: 1.6-2.6) at 8.0 years. Microsimulation reported a 40-year-old undergoing the Ross procedure to have a life expectancy of 35.4 years and event-free life expectancy of 26.6 years. Conclusions: Ross procedure in nonelderly adults is associated with low mortality and low risk of adverse events both at short- and long-term follow-up. The surgical community must prioritize a large, expertize-based randomized controlled trial to definitively address the risks and benefits of the Ross procedure compared to conventional aortic valve replacement.

Original languageEnglish (US)
JournalJournal of Cardiac Surgery
DOIs
StatePublished - Jan 1 2019

Fingerprint

Meta-Analysis
Confidence Intervals
Life Expectancy
Hemorrhage
Mortality
Endocarditis
Embolism
Aortic Valve
Thrombosis
Randomized Controlled Trials
Stroke
Databases

Keywords

  • surgical history
  • valve repair/replacement

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Sibilio, S., Koziarz, A., Belley-Côté, E. P., McClure, G. R., MacIsaac, S., Reza, S. J., ... Whitlock, R. P. (2019). Outcomes after Ross procedure in adult patients: A meta-analysis and microsimulation. Journal of Cardiac Surgery. https://doi.org/10.1111/jocs.14020

Outcomes after Ross procedure in adult patients : A meta-analysis and microsimulation. / Sibilio, Serena; Koziarz, Alex; Belley-Côté, Emilie P.; McClure, Graham R.; MacIsaac, Sarah; Reza, Seleman J.; Um, Kevin J.; Lengyel, Alexandra; Mendoza, Pablo; Alsagheir, Ali; Alraddadi, Hatim; Gupta, Saurabh; Schneider, Adriaan W.; Patel, Parth M.; Brown, John; Chu, Michael W.A.; Peterson, Mark D.; Ouzounian, Maral; Paparella, Domenico; El-Hamamsy, Ismail; Whitlock, Richard P.

In: Journal of Cardiac Surgery, 01.01.2019.

Research output: Contribution to journalArticle

Sibilio, S, Koziarz, A, Belley-Côté, EP, McClure, GR, MacIsaac, S, Reza, SJ, Um, KJ, Lengyel, A, Mendoza, P, Alsagheir, A, Alraddadi, H, Gupta, S, Schneider, AW, Patel, PM, Brown, J, Chu, MWA, Peterson, MD, Ouzounian, M, Paparella, D, El-Hamamsy, I & Whitlock, RP 2019, 'Outcomes after Ross procedure in adult patients: A meta-analysis and microsimulation', Journal of Cardiac Surgery. https://doi.org/10.1111/jocs.14020
Sibilio, Serena ; Koziarz, Alex ; Belley-Côté, Emilie P. ; McClure, Graham R. ; MacIsaac, Sarah ; Reza, Seleman J. ; Um, Kevin J. ; Lengyel, Alexandra ; Mendoza, Pablo ; Alsagheir, Ali ; Alraddadi, Hatim ; Gupta, Saurabh ; Schneider, Adriaan W. ; Patel, Parth M. ; Brown, John ; Chu, Michael W.A. ; Peterson, Mark D. ; Ouzounian, Maral ; Paparella, Domenico ; El-Hamamsy, Ismail ; Whitlock, Richard P. / Outcomes after Ross procedure in adult patients : A meta-analysis and microsimulation. In: Journal of Cardiac Surgery. 2019.
@article{e8e4c064f4c94beca91c682c2da95df3,
title = "Outcomes after Ross procedure in adult patients: A meta-analysis and microsimulation",
abstract = "Objective: We conducted a meta-analysis to estimate the risk of adverse events, life expectancy, and event-free life expectancy after the Ross procedure in adults. Methods: We searched databases for reports evaluating the Ross procedure in patients aged more than or equal to 16 years of age. A microsimulation model was used to evaluate age- and gender-specific life expectancy for patients undergoing the Ross procedure. Results: Data were pooled from 63 articles totaling 19 155 patients from 20 countries. Perioperative mortality was 2.5{\%} (95{\%} confidence interval [CI]: 1.9-3.1; N = 9978). We found a mortality risk of 5.9{\%} (95{\%} CI: 4.8-7.2) at a mean follow-up of 7.2 years (N = 7573). The rate of perioperative clinically significant bleeding was 1.0{\%} (95{\%} CI: 0.1-3.0); re-exploration for bleeding 4.6{\%} (95{\%} CI: 3.1-6.3); postoperative clinically significant bleeding from 30 days until a mean of 7.1 years was 0.5{\%} (95{\%} CI: 0.2-1.0). At a mean of 6.9 years of follow-up, reintervention rate of any operated valve was 7.9{\%} (95{\%} CI: 5.7-10.3). The risk of valve thrombosis was 0.3{\%} (95{\%} CI: 0.2-0.5) at 7.6 years; peripheral embolism 0.3{\%} (95{\%} CI: 0.2-0.4) at 6.4 years; stroke 0.9{\%} (95{\%} CI: 0.7-1.2) at 6.5 years; and endocarditis 2.1{\%} (95{\%} CI: 1.6-2.6) at 8.0 years. Microsimulation reported a 40-year-old undergoing the Ross procedure to have a life expectancy of 35.4 years and event-free life expectancy of 26.6 years. Conclusions: Ross procedure in nonelderly adults is associated with low mortality and low risk of adverse events both at short- and long-term follow-up. The surgical community must prioritize a large, expertize-based randomized controlled trial to definitively address the risks and benefits of the Ross procedure compared to conventional aortic valve replacement.",
keywords = "surgical history, valve repair/replacement",
author = "Serena Sibilio and Alex Koziarz and Belley-C{\^o}t{\'e}, {Emilie P.} and McClure, {Graham R.} and Sarah MacIsaac and Reza, {Seleman J.} and Um, {Kevin J.} and Alexandra Lengyel and Pablo Mendoza and Ali Alsagheir and Hatim Alraddadi and Saurabh Gupta and Schneider, {Adriaan W.} and Patel, {Parth M.} and John Brown and Chu, {Michael W.A.} and Peterson, {Mark D.} and Maral Ouzounian and Domenico Paparella and Ismail El-Hamamsy and Whitlock, {Richard P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jocs.14020",
language = "English (US)",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Outcomes after Ross procedure in adult patients

T2 - A meta-analysis and microsimulation

AU - Sibilio, Serena

AU - Koziarz, Alex

AU - Belley-Côté, Emilie P.

AU - McClure, Graham R.

AU - MacIsaac, Sarah

AU - Reza, Seleman J.

AU - Um, Kevin J.

AU - Lengyel, Alexandra

AU - Mendoza, Pablo

AU - Alsagheir, Ali

AU - Alraddadi, Hatim

AU - Gupta, Saurabh

AU - Schneider, Adriaan W.

AU - Patel, Parth M.

AU - Brown, John

AU - Chu, Michael W.A.

AU - Peterson, Mark D.

AU - Ouzounian, Maral

AU - Paparella, Domenico

AU - El-Hamamsy, Ismail

AU - Whitlock, Richard P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: We conducted a meta-analysis to estimate the risk of adverse events, life expectancy, and event-free life expectancy after the Ross procedure in adults. Methods: We searched databases for reports evaluating the Ross procedure in patients aged more than or equal to 16 years of age. A microsimulation model was used to evaluate age- and gender-specific life expectancy for patients undergoing the Ross procedure. Results: Data were pooled from 63 articles totaling 19 155 patients from 20 countries. Perioperative mortality was 2.5% (95% confidence interval [CI]: 1.9-3.1; N = 9978). We found a mortality risk of 5.9% (95% CI: 4.8-7.2) at a mean follow-up of 7.2 years (N = 7573). The rate of perioperative clinically significant bleeding was 1.0% (95% CI: 0.1-3.0); re-exploration for bleeding 4.6% (95% CI: 3.1-6.3); postoperative clinically significant bleeding from 30 days until a mean of 7.1 years was 0.5% (95% CI: 0.2-1.0). At a mean of 6.9 years of follow-up, reintervention rate of any operated valve was 7.9% (95% CI: 5.7-10.3). The risk of valve thrombosis was 0.3% (95% CI: 0.2-0.5) at 7.6 years; peripheral embolism 0.3% (95% CI: 0.2-0.4) at 6.4 years; stroke 0.9% (95% CI: 0.7-1.2) at 6.5 years; and endocarditis 2.1% (95% CI: 1.6-2.6) at 8.0 years. Microsimulation reported a 40-year-old undergoing the Ross procedure to have a life expectancy of 35.4 years and event-free life expectancy of 26.6 years. Conclusions: Ross procedure in nonelderly adults is associated with low mortality and low risk of adverse events both at short- and long-term follow-up. The surgical community must prioritize a large, expertize-based randomized controlled trial to definitively address the risks and benefits of the Ross procedure compared to conventional aortic valve replacement.

AB - Objective: We conducted a meta-analysis to estimate the risk of adverse events, life expectancy, and event-free life expectancy after the Ross procedure in adults. Methods: We searched databases for reports evaluating the Ross procedure in patients aged more than or equal to 16 years of age. A microsimulation model was used to evaluate age- and gender-specific life expectancy for patients undergoing the Ross procedure. Results: Data were pooled from 63 articles totaling 19 155 patients from 20 countries. Perioperative mortality was 2.5% (95% confidence interval [CI]: 1.9-3.1; N = 9978). We found a mortality risk of 5.9% (95% CI: 4.8-7.2) at a mean follow-up of 7.2 years (N = 7573). The rate of perioperative clinically significant bleeding was 1.0% (95% CI: 0.1-3.0); re-exploration for bleeding 4.6% (95% CI: 3.1-6.3); postoperative clinically significant bleeding from 30 days until a mean of 7.1 years was 0.5% (95% CI: 0.2-1.0). At a mean of 6.9 years of follow-up, reintervention rate of any operated valve was 7.9% (95% CI: 5.7-10.3). The risk of valve thrombosis was 0.3% (95% CI: 0.2-0.5) at 7.6 years; peripheral embolism 0.3% (95% CI: 0.2-0.4) at 6.4 years; stroke 0.9% (95% CI: 0.7-1.2) at 6.5 years; and endocarditis 2.1% (95% CI: 1.6-2.6) at 8.0 years. Microsimulation reported a 40-year-old undergoing the Ross procedure to have a life expectancy of 35.4 years and event-free life expectancy of 26.6 years. Conclusions: Ross procedure in nonelderly adults is associated with low mortality and low risk of adverse events both at short- and long-term follow-up. The surgical community must prioritize a large, expertize-based randomized controlled trial to definitively address the risks and benefits of the Ross procedure compared to conventional aortic valve replacement.

KW - surgical history

KW - valve repair/replacement

UR - http://www.scopus.com/inward/record.url?scp=85062954351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062954351&partnerID=8YFLogxK

U2 - 10.1111/jocs.14020

DO - 10.1111/jocs.14020

M3 - Article

C2 - 30866116

AN - SCOPUS:85062954351

JO - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

ER -